Moleculin Reports Independent Assessment Confirms No Cardiotoxicity Of Annamycin In 90 Subjects
Jan 13 (Reuters) - Moleculin Biotech Inc MBRX.O:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.